## **Kluwer Patent Blog**

## USA: In re Nexium (Esomeprazole) Antitrust Litigation, United States Court of Appeals, First Circuit, Nos. 15-2005, 21 November 2016

Linda O'Brien (CCH) · Thursday, December 8th, 2016

Purchasers of AstraZeneca LP's heartburn medication Nexium were not entitled to a new trial to their challenge of "reverse payment" agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. Court of Appeals in Boston has decided. The plaintiffs' argument that the trial court improperly limited their causation theory was rejected and the jury verdict was therefore affirmed (In re Nexium (Esomeprazole) Antitrust Litigation, November 21, 2016, Lynch, S.).

A full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

## Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Thursday, December 8th, 2016 at 11:00 am and is filed under United States of America

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.